Electrical system for treating the subject

Abstract

The system and method of the present disclosure relate to treating disease states, particularly different types of cancer, by the application of low-energy emission therapy. The device and method provide a treatment for the disease state of a patient, particularly a patient of a type of cancer, by applying specific and disease-specific low-energy high-frequency radiation to the patient. The device uses a high-precision frequency synthesizer to generate amplitude-modulated radio frequency radiation at an identified tumor-specific frequency for application to the patient during treatment.

Description

Technology Field

[0001] Cross-reference regarding related applications

[0002] The present application claims priority under 35 USC §119(e) to U.S. provisional application serial number 62 / 923,908 filed on October 21, 2019 and U.S. provisional application serial number 62 / 934,212 filed on November 12, 2019, the entire contents of which are incorporated herein by reference.

[0003] Field of invention

[0004] The present invention relates to a system and method for treating a subject using low-energy high-frequency radiation. The electronic system and its programmed control have therapeutic applications for affecting cellular function (or dysfunction), including directly or indirectly influencing cancer cell growth or proliferation in warm-blooded mammalian subjects. The apparatus and method of the present invention provide treatment for different types of cancer by applying an electromagnetic field amplitude-modulated at a specific, cancer-specific frequency to a patient. Background Technology

[0005] European Patent EP 0 592 851 B1 and corresponding patents and patent applications relating to the effects of ultra-low energy electromagnetic fields on subjects, and various publications mentioned in this specification are referenced. A number of additional publications relating to the effects of ultra-low energy electromagnetic fields on patients suffering from insomnia and / or anxiety disorders are provided and are as follows:

[0006] · Koziol, JA, Erman, M., Pasche B., Hajdukovic R., Mitler, MM, (1993), “Assessing a changepoint in a sequence of repeated measurements with application to a low-energy emission therapy sleep study”.J. Applied Statistics 20: 393-400;

[0007] ·        Amato, D., Pasche, B., (1993), "An evaluation of the safety of low energy emission therapy". Compr Ther 19: 242-247;

[0008] · Higgs , L. , Reite , M. , Barbault , A. , Lebet , JP , Rossel , C. , Amato , D. , Dafni , U. , Pasche . B., (1994), "Subjective and Objective Relaxation Effects of Low Energy Emission Therapy". Stress Medicine 10: 5-13;

[0009] · Reite , M. , Higgs , L , Lebet , JP , Barbault , A. , Rossel , C. , Kuster , N. , Dafni , U. , Amato , D. , Pasche , B. , (1994). Bioelectromagnetics 15: 67-7

[0010] ·        Lebet, JP, Barbault, A., Rossel, C., Tomic, Z., Reite, M., Higgs, L., Dafni, U., Amato, D., Pasche, B., (1996), "Electroencephalographic changes following low energy emission therapy". Ann Biomed Eng 24: 424-429;

[0011] · Pasche, B., Erman, M., Hayduk, R., Mitler, M., Reite, M., Higgs, L., Dafni, U., Amato, D., Rossel, C., Kuster, N., Barbault, A., Lebet, JP, (1996), “Effects of Low Energy Emission Therapy in chronic psychophysiological insomnia”. Sleep 19: 327-336;

[0012] · Kelly, T.L., Kripke, D.F., Hayduk, R., Ryman, D., Pasche, B., Barbault, A., (1997), “Bright light and LEET effects on circadian rhythms, sleep and cognitive performance”. Stress Medicine 13: 251-258; and

[0013] · Pasche, B., Barbault, A., (2003), “Low-Energy Emission Therapy Current Status and Future Directions. In Bioelectromagnetic Medicine ", Rosch, PJ, Markov, MS (eds.), pages 321-327, Marcel Dekker, Inc.: New York, NY

[0014] The above publications relate to the initial device, system, and use thereof described in EP 0 592 851 B1.

[0015] Electromagnetic energy generating devices and the use of electromagnetic energy for treating living mammalian subjects with cancerous cells described in the literature include: U.S. Patent No. 5,908,441, granted to James E. Baer on June 1, 1999, and the references cited herein, and the so-called “NovoCure technology” involving the in vivo implantation of electrodes on either side of tumor growth. The method of this patent is invasive because it involves implanting electrodes into the patient. This may also make it unsuitable for the treatment of some types of tumors. This patent does not account for the ultra-low energy emission of electromagnetic energy accompanied by amplitude-modulated high-frequency carrier signals required in relation to the present invention.

[0016] U.S. Patent No. 5,690,692, titled “Bioactive Frequency Generator and Method,” granted on November 25, 1997, describes programmable control instructing a frequency synthesizer to generate current from a specific precision frequency signal or a series of specific precision frequency signals having a square waveform within an accuracy of 0.001 Hz. This patent considers amplifying the voltage of the generated signal and applying the signal to a subject using electrodes maintained by or otherwise connected to the subject at a specific precision frequency or sequentially at a series of specific precision frequencies. This patent also does not consider the ultra-low energy emission of electromagnetic energy accompanied by an amplitude-modulated high-frequency carrier signal required in connection with the present invention.

[0017] U.S. Patent No. 8,977,365, granted on March 10, 2015, under the title “Electronic system for influencing cellular function in warm-blooded mammalian subjects,” describes an electronic system that can be activated by power as being useful for influencing cellular function or dysfunction in warm-blooded mammalian subjects. The system comprises one or more controllable low-energy high-frequency (HF) carrier signal generator circuits, one or more data processors for receiving control information, one or more amplitude modulation control generators, and one or more amplitude modulation frequency control generators. The amplitude modulation frequency control generators are modified to accurately control the frequency of amplitude modulation within an accuracy of at least 1,000 ppm, most preferably within about 1 ppm, relative to one or more determined or predetermined reference amplitude modulation frequencies. Although the improved electronic system and its programmed control according to U.S. Patent No. 8,977,365 have been shown to directly or indirectly affect cancerous cell growth or proliferation in warm-blooded mammalian subjects, this patent utilizes an analog synthesizer to generate a return signal and produces an advanced output signal.

[0018] The apparatus and method of the present invention are generally non-invasive without the need for implanted electrodes. The method and apparatus provided herein apply ultra-low energy emission of electromagnetic energy having a precisely determined amplitude modulation frequency to a patient, particularly a patient for cancer treatment.

[0019] There is a great need for improved cancer therapies to expand treatment options for cancer. This need is particularly urgent for the treatment of refractory cancers, cancers for which other treatment options have lost effectiveness, metastatic cancers, and cancers that are difficult to treat or resistant to treatment, such as metastases to the bone and brain. The systems and methods of the present disclosure provide a treatment for cancer that meets these and other needs, as discussed in detail below. means of solving the problem

[0020] The systems and methods of the present disclosure relate to the treatment of different types of cancer by the application of low-energy release therapy. These systems and methods were determined to seek therapeutic applications for affecting other cellular functions (or dysfunctions), including, as well as affecting, directly or indirectly, cancerous cell growth or proliferation in warm-blooded mammalian subjects, as well as affecting, more particularly, cancerous cell growth or proliferation. Direct or indirect effects on cancerous cell growth may involve, but are not necessarily limited to, the prophylactic avoidance of cancerous cell formation, affecting cellular function, e.g., affecting leukocyte cell function that may cause inhibition of cancerous cell growth or proliferation, and / or the death of cancerous cells received in warm-blooded mammalian subjects.

[0021] In one aspect, the present invention provides an apparatus for treating a subject suffering from cancer, the apparatus comprising: (i) a conductive applicator configured to apply low-energy high-frequency radiation comprising one or more amplitude-modulated output signals to the subject; and (ii) a frequency synthesizer configured to generate one or more amplitude-modulated output signals by generating a carrier frequency signal having a carrier frequency of about 1 KHz to 5000 MHz and an amplitude-modulated frequency signal having an amplitude-modulated frequency of about 0.1 Hz to about 150,000 Hz, selected to be a cancer-specific frequency.

[0022] The frequency synthesizer comprises: (i) a digital carrier frequency synthesizer configured to output a carrier frequency signal; (ii) a digital modulation frequency synthesizer configured to output one or more amplitude modulation frequency signals; (iii) an arithmetic logic unit (ALU) configured to numerically calculate one or more digital modulation signals in real time from the carrier frequency signal and the modulation frequency digital signal; and (iv) a digital-to-analog converter (DAC) configured to convert one or more digital modulation signals into one or more amplitude modulated output signals.

[0023] In another aspect, the present invention provides a method for treating a subject suffering from cancer, the method comprising exposing the subject to low-energy high-frequency radiation, wherein the low-energy high-frequency radiation comprises one or more amplitude-modulated output signals, wherein the one or more amplitude-modulated output signal(s) have a carrier frequency of about 1 KHz to 5000 MHz; and have an amplitude-modulated frequency of about 0.1 Hz to about 150,000 Hz, wherein the amplitude-modulated frequency is selected to be a cancer-specific frequency; Here, the subject is processed by one or more of the arm-specific amplitude modulation frequencies disclosed herein, or 10 or more, 15 or more, 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, or 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more.

[0024] In another aspect, the apparatus and method disclosed herein use a specific absorption rate (SAR) of low-energy high-frequency radiation absorbed by a patient, which is about 1 microwatt per kilogram of tissue to about 50 watts per kilogram of tissue, about 100 microwatts per kilogram of tissue to about 10 watts per kilogram of tissue, or about 0.02 milliwatts per kilogram of tissue to about 400 milliwatts per kilogram of tissue. The low-energy high-frequency radiation may be applied to a subject receiving treatment through an electrically conductive probe that may be configured to come into contact with the subject's mucous membrane or the subject's skin.

[0025] In another aspect, the frequency synthesizer is a digital frequency synthesizer comprising: a digital carrier frequency synthesizer configured to output a carrier frequency signal; a digital modulation frequency synthesizer configured to output one or more amplitude modulation frequency signals; an arithmetic logic unit (ALU) configured to numerically calculate one or more digital modulation signals in real time from the carrier frequency signal and the modulation frequency digital signal; and a digital-to-analog converter (DAC) configured to convert one or more digital modulation signals into one or more amplitude modulated output signals.

[0026] The methods and devices disclosed herein can be used to treat a wide variety of cancers, including breast cancer, neuroendocrine tumors, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, lung cancer, kidney cancer, ovarian cancer, bladder cancer, leiomyosarcoma, multiple myeloma, lymphoma, leukemia, chronic lymphoma, brain cancer, and colorectal cancer. Brief explanation of the drawing

[0027] Figure 1 shows an exemplary system for applying low-energy electromagnetic radiation to a target. FIG. 2 illustrates a block diagram of an exemplary emission device for applying low-energy electromagnetic radiation to a target. FIG. 3 illustrates a block diagram of an exemplary digital frequency synthesizer of the emission device of FIG. 2. FIG. 4 illustrates a block diagram of the controller of the emission device of FIG. 2. Figure 5 illustrates an exemplary amplitude-modulated output signal. FIG. 6 illustrates a block diagram of internal hardware included in any electronic component of the emitting device of FIG. 2. Specific details for implementing the invention

[0028] As used in this document, the singular forms "a," "an," and "the" include plural referents unless the context otherwise indicates. Unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as generally understood by a person skilled in the art. As used in this document, the terms "comprising" or "comprises" mean "including" (or "includes"), but are not limited thereto. As used in this document, the term "exemplary" is intended to mean "by example" and is not intended to indicate that a specific exemplary item is preferred or required.

[0029] Where terms such as “first” and “second” are used in this document to modify nouns or phrases, such use is merely to distinguish one item from another and is not intended to require a sequential order unless specifically stated otherwise. The term “about” used in relation to numerical values ​​is intended to include values ​​that are close to a number but not exactly a number. For example, in some embodiments, the term “about” may include values ​​within + / - 10 percent of that value.

[0030] The present disclosure relates to a method and apparatus for using low-energy emission therapy involving the application of a low-energy radio frequency (RF) electromagnetic field to a warm-blooded mammalian subject to treat various forms of cancer, generally using a specific frequency of radio frequency (RF) radiation. The disclosures of EP 0 592 851 B1 and U.S. Patent No. 8,977,365 ("'365 patent") are incorporated herein by reference in their entirety.

[0031] Terms related to this document include the following:

[0032] "Electronic device" or "computing device" refers to a device or system comprising a processor and memory. Each device may have its own processor and / or memory, or the processor and / or memory may be shared with other devices, such as in a virtual machine or array of containers. Memory will contain or receive programming instructions that cause the electronic device to perform one or more actions according to programming instructions when executed by the processor. Examples of electronic devices include personal computers, servers, mainframes, virtual machines, containers, game systems, televisions, digital home assistants, and mobile electronic devices such as smartphones, fitness tracking devices, and wearable virtual reality devices. Electronic devices may also include internet-connected wearables such as smart clocks, smart clothing, and smart glasses. The electronic device may also be embedded in a product designed to be used by a person during treatment, such as a spoon-shaped probe, and may be connected to the subject by any means providing appropriate frequency transmission to the subject, including but not limited to a device that comes into direct contact with the subject's mucous membrane, such as a spoon-shaped or other shaped probe, a device that comes into contact with the subject's skin, such as a band or patch, or means that transmits frequencies without direct contact with the subject. In a client-server arrangement, the client device and the server are electronic devices, wherein the server contains commands and / or data accessed by the client device via one or more communication links in one or more communication networks. In a virtual machine arrangement, the server may be an electronic device, and each virtual machine or container may also be considered an electronic device. In the following detailed description, the client device, server device, virtual machine, or container may be simply referred to as "device" for brevity. Additional elements that may be included in the electronic device will be discussed below in the context of FIG. 6.

[0033] The terms “processor” and “processing unit” refer to hardware components of an electronic device configured to execute programming instructions. Unless specifically stated otherwise, the singular terms “processor” and “processing unit” are intended to include both single-processing unit implementations and implementations in which multiple processing units perform the process together or collectively.

[0034] Terms such as “memory,” “memory device,” “data storage,” and “data storage facility” each refer to a non-transient device in which computer-readable data, programming instructions, or both are stored. Unless otherwise specifically stated, terms such as “memory,” “memory device,” “data storage,” and “data storage facility” are intended to include single device embodiments, embodiments in which multiple memory devices store sets of data or instructions together or collectively, as well as individual sectors within such devices.

[0035] As used herein, the terms “treat,” “treating,” or “stimulating” refer to any process, action, authorization, therapy, etc. in which medical assistance is provided for the purpose of directly or indirectly improving the condition of a subject (or patient), including humans, or slowing the progression of the subject’s condition or disability, or improving at least one symptom of the disease or disability being treated.

[0036] As used herein, the terms “patient” or “subject” refer to any animal, preferably a mammal, more preferably a human, including but not limited to livestock and farm animals, primates and humans, and include, for example, humans, non-human primates, cattle, horses, pigs, sheep, goats, dogs, cats, or rodents such as rats and mice.

[0037] The apparatus and method of the present invention provide treatment for a patient's disease state, particularly a type of cancer, by applying special and disease-specific low-energy high-frequency radiation to the patient. The apparatus uses a high-precision frequency synthesizer to generate a radio frequency EMF amplitude-modulated at an identified tumor-specific frequency for application to the patient during treatment.

[0038] The system of the present disclosure is used to affect cellular function or dysfunction in warm-blooded mammalian subjects. The system includes one or more controllable low-energy electromagnetic energy generator circuits for generating one or more radio frequency output signals. One or more controller circuits are provided that include or communicate with one or more generator circuits for receiving control information from a source of programmed control information. One or more generator circuits may include a programmable field-programmable gate array (FPGA) configured for the digital synthesis of a complete modulated digital signal using one or more direct digital synthesizers (DDS). The FPGA generates a modulated digital signal by numerical calculation based on a carrier frequency digital signal and a modulation frequency digital signal. In a significant aspect of the present invention, the fully modulated digital signal generated by the FPGA is modified to accurately control the amplitude modulation frequency with respect to one or more determined or predetermined reference amplitude modulation frequencies selected within the range of 0.1 Hz to 150,000 Hz, more preferably within the range of 100 Hz to 99,000 Hz, with an accuracy of within 1 part per 10,000, more preferably within the accuracy of within 1 part per 100,000, and most preferably within the accuracy of within 1 part per 1,000,000 (ppm), under long-term stability of + / - 5.3 ppm. The FPGA synthesis of the fully modulated digital signal also enables the simultaneous combination of different types of modulation and different modulation frequencies. Furthermore, such digital synthesis also allows the resolution to become independent of the actual modulation frequency. The fully modulated digital signal can be converted into an analog RF output signal using a suitable digital-to-analog converter (DAC).The system also includes a connection or coupling location for connecting or coupling to, or connected or coupled to, an electrically conductive application device for applying one or more amplitude-modulated low-energy emissions at the precisely controlled modulation frequency to a warm-blooded mammalian subject.

[0039] Although the present disclosure describes the use of modulated digital signals, analog forms and analog modulated signals may also be used as described in the '365 patent.

[0040] As used herein, the term “precisely controlled” means that modulated low-energy electromagnetic emissions must be modulated within a resolution of, preferably, about 0.1 Hz, more preferably about 0.05 Hz, and most preferably about 3 to about 5 milliHz (0.003 to 0.005 Hz) of the intended determined or predetermined modulation frequency. For example, if one or more determined or predetermined modulation frequencies to be applied to a warm-blooded mammalian subject is about 2000 Hz, precise control must cause such modulated low-energy emissions to occur at frequencies between about 1999.995 to 1999.997 Hz and about 2000.003 to 2000.005 Hz.

[0041] The important thing is that the emission is carried out at a very low and safe energy level, resulting in a low absorption level. This is believed to be because the physiological exchange or flow of electrical impulses within warm-blooded animals (which are to be affected by the application of the emission of the present invention) is similar even at ultra-low energy levels. In any case, in the area (the contact or proximity induction location between the subject receiving treatment and the electrically conductive application device or nearby), the specific absorption rate (SAR) must be between about 0.02 and about 400 mW / kg.

[0042] To achieve the intended biological therapeutic effect, it is more important that the stability of the release be maintained during release, and that this stability is determined by dividing the relative deviation of the frequency by the desired frequency, preferably at least about 10 -5 , more preferably at least about 10 -6 , most preferably at least about 10 -7 It must be stable. For example, 0.01 Hz (deviation) / 1,000 Hz (desired frequency) = 10 -5 .

[0043] Now, looking at Fig. 1, a system for cancer treatment of a subject ( 100 ) is the object( 110 ) emitting device communicating with ( 101 It may include ). Emission device ( 101 ) is a probe( 102 through ) the object( 110 It may be configured to provide RF electromagnetic radiation (hereinafter "output signal") modulated at a desired frequency to ). In certain embodiments, the output signal has various control parameters, without limitation, such as the duration of the session, the sequence of applied frequencies during the session, and the duration of each applied frequency. The applied frequencies and their corresponding durations may be determined according to the type of tumor being treated. Specifically, the selection of such output signal is based on an output signal predetermined to provide a beneficial therapeutic effect to a number of subjects or patients pre-diagnosed with an identified poor health condition. The aforementioned output signal is an emitting device ( 101 It can be provided by ). Without limitation, different types of modulation such as amplitude modulation, frequency modulation, and phase modulation may be used. Preferably, the output signal is generated at a tumor-specific amplitude modulation (AM) frequency.

[0044] In a specific implementation, probe (102 The device may be an electrically conductive application device for applying one or more electromagnetic emissions to a warm-blooded mammalian subject, for example, through conductive, inductive, capacitive, radioactive coupling, or a combination thereof. One form of the application device may include an electrically conductive probe, for example, a mouthpiece inserted into the oral cavity of the subject receiving treatment. The probe may be modified to apply to any mucous membrane of the subject (e.g., located in the oral cavity, nasal side, eyeball, urethra, anus, and / or vaginal cavity, or within a surface), modified to make physical contact with the patient's skin (e.g., an insulated probe in contact with the subject's ear, head, neck, etc.), or any other means.

[0045] In another embodiment, the EMF output signal is applied to the target through an antenna that is not in direct physical contact with the target. In this embodiment, the target may be in a chamber exposed to the EMF output signal, or the target may be kept in close proximity to a broadcast antenna for the EMF output signal during the treatment(s).

[0046] probe 102 ) is, for example, a coaxial cable ( 104 ) through the emission device ( 101 It can be connected to ).

[0047] Now, looking at Fig. 2, an exemplary emission device ( 101 A block diagram illustrating ) is shown. As shown in FIG. 2, the emission device ( 101 ) is a controller( 201 ), memory( 202 ), vibrator( 203 ), digital frequency synthesizer( 204 ), Digital-to-Analog Converter (DAC)( 205 ), amplifier( 206 ), filter( 207 ), directional coupler( 208 ), impedance converter( 209 ), everyone(210 ), and communication interface ( 211 Includes ). Optionally, the emission device (101) also includes a display ( 212 ), user interface( 213 ), and other output part(s)( 214 It may include )(e.g., LED, speaker, etc.).

[0048] In a specific implementation, the controller ( 201 ) is a emission device ( 101 A discharge device that controls the operation of one or more parts of ) 101 It can operate as a controller for ). Controller( 201 ) is a emission device ( 101 It can be coupled to various parts of the controller (for example, address buses, data buses, and input / output lines, etc., not shown here) so as to be communicative. 201 The timing of ) can be provided by a system clock (not shown herein) running at any clock frequency suitable for the processor type. Generally, the controller ( 201 ) is a probe( 102 An emission device (to produce modulated low-energy electromagnetic emission of a desired form to be applied to a target object through ) 101 It is configured to control the operation of one or more parts of ).

[0049] The level of applied power is preferably such that the Specific Absorption Rate (SAR) of the energy absorbed by the patient is about 1 microwatt per kilogram of tissue to about 50 watts per kilogram of tissue, and the controller ( 201It is controlled by ). Preferably, the power level is controlled to induce a SAR of about 100 microwatts per kilogram of tissue to about 10 watts per kilogram of tissue. Most preferably, the power level is controlled to induce a SAR of about 0.02 milliwatts per kilogram of tissue to about 400 milliwatts per kilogram of tissue. Such SAR may be present in any tissue of the patient.

[0050] The frequency of electromagnetic radiation can be tumor-specific and is explained in more detail below.

[0051] Now, looking at Fig. 4, a typical controller ( 400 ) processor( 402 ), Random Access Memory (RAM)( 403 ), non-volatile memory( 404 ), device-specific circuit( 401 ), and input / output (I / O) interfaces ( 405 It is urbanized together with ). Alternatively, RAM( 403 ) and / or non-volatile memory (404) is a device-specific circuit ( 401 ) and I / O interface( 405 Like a processor( 402 It can be contained in ). Processor( 402 ) may include, for example, off-the-shelf microprocessors, custom processors, FPGAs (Field Programmable Gate Arrays), ASICs (Application Specific Integrated Circuits), discrete logic, etc. RAM( 403 ) is typically used to hold mutable data, stack data, executable instructions, etc.

[0052] According to various approaches, non-volatile memory ( 404) may include any type of non-volatile memory, such as, for example, but not limited to, EEPROM (Electrically Erasable Programmable Read Only Memory), flash PROM (Programmable Read Only Memory), battery backup RAM, hard disk drives, etc. However, non-volatile memory ( 404 ) is typically a processor ( 402 It is used to hold arbitrary non-volatile data and executable firmware containing programming instructions that can be executed to perform specific functions.

[0053] In some implementations, the I / O interface ( 405 ) is a processor( 402 It may include a communication interface that enables the controller to communicate with a device outside the controller. Examples of communication interfaces may include, but are not limited to, serial interfaces such as RS-232, USB (Universal Serial Bus), SCSI (Small Computer Systems Interface), Ethernet, RS-422, or wireless communication interfaces such as Wi-Fi, Bluetooth, near-field communication (NFC), or other wireless interfaces. 400 ) is a communication interface ( in any communication protocol such as ADI (Automation / Drive Interface) 405 It can communicate with external devices through ).

[0054] According to the various approaches described and / or proposed herein, the controller may have a single processor or controller, or may include multiple processors or controllers, or multiple cores on a processor chip.

[0055] memory ( 202) can be any storage device capable of storing information for later retrieval, and the emission device ( 101 It can be configured to store data for the operation of ). For example, memory ( 202 ) may be a magnetic media-based storage device (e.g., card, tape, disk, or drum), a semiconductor memory-based storage device [e.g., eraseable and programmable read memory (EPROM), electro-eraseable and programmable read memory (EEPROM), or non-volatile random access memory (RAM)], a mechanical information storage device (e.g., punched card, cam, etc.), and / or an optical storage device [e.g., compact disc read-only memory (CD ROM)].

[0056] memory ( 202 ) is a probe( 102 The control information may include various controllable parameters [used by the controller (201)] of the modulated low-energy radiation to be applied to the subject. These controllable parameters include, for example, but not limited to, the frequency and amplitude of the output signal, the duration of the emission, the level of the emission power, the emission duty cycle (i.e., the ratio of the operating time to the stopping time of the pulsed emission applied during treatment), the order of application of different modulation frequencies for special application, and the total number of treatments prescribed to the special subject and the duration of each treatment, and combinations thereof.

[0057] For example, FIG. 5 illustrates an exemplary amplitude-modulated output signal that can be applied to an object in a sequence of applications of different modulation frequencies ranging from a minimum frequency to a maximum frequency, with each modulation frequency applied for a predetermined duration. As discussed above, the present disclosure describes the use of digital signals (carrier frequency signals and / or modulation frequency signals), but the use of analog signals to generate the modulation frequencies of the present disclosure is within the scope of the present disclosure. Methods and systems for generating analog signals are described in the '365 patent.

[0058] In a specific embodiment, the carrier frequency digital signal and the modulation frequency digital signal (described below) are probes (amplitude-modulated output signals). 102 It may be selected to drive the). The carrier frequency digital signal may be about 1 KHz to 5000 MHz, or about 0.1 to 1000 MHz, or about 1 to 500 MHz, or about 1 to 100 MHz, or about 5 to 50 MHz, or about 10 MHz to about 40 MHz, or about 15 MHz to about 30 MHz, or any other frequency (e.g., 27 MHz) at which the body of the subject can be utilized as an antenna. One or more modulation frequencies may be emitted simultaneously or sequenced to form a modulation signal. The modulation frequency digital signal may be about 0.1 Hz to 150,000 Hz, more preferably within 100 Hz to 99,000 Hz, and may be determined and selected based on the disease state or type of cancer to be treated (described below).

[0059] In a specific implementation example, memory ( 202 ) is also a emitting device ( 101Event data corresponding to ), user information (e.g., authentication data, medical information, etc.), troubleshooting guidelines, etc., can be stored. Examples of event data may include, without limitation, error logs, usage history and related data, processing information, battery information, etc. Such event data can be used to monitor patient compliance and detect functional and device handling problems, etc. Memory ( 202 Information or data stored in ) directly and / or indirectly (e.g., emission device ( 101 communication interface (via a docking station for charging ) 211 It can be retrieved using ). Then, a physician or other clinician can use this information to evaluate the patient's treatment adherence and effectiveness. Treatment information may include, for example, the number of authorized treatments during a given time period; the actual time and date of each treatment; the number of treatments attempted; treatment adherence (i.e., whether the probe was in place during the treatment session); and the cumulative dose of a specific modulation frequency.

[0060] Digital frequency synthesizer ( 204 ) may be a programmable logic device (PLD), such as a field programmable gate array (FPGA), and may be configured to provide digital synthesis of a fully modulated output signal. Those skilled in the art will understand that if the digital synthesis implementation is implemented on a different PLD, it can be used similarly. FIG. 3 is an exemplary digital frequency synthesizer ( 204 Example of a block diagram of ).

[0061] As shown in FIG. 3, a digital frequency synthesizer ( 204 ) is a Carrier Frequency Direct Digital Synthesizer (DDS)( 301 ), modulation frequency DDS( 302 ), one or more control registers ( 303), Phase-locked loop (PLL) frequency multiplier ( 304 ), and Arithmetic Logic Unit (ALU)( 305 It may include ).

[0062] Direct Digital Synthesis (DDS) is an increasingly popular technology for radio frequency (RF) signal generation due to its high performance and low cost. DDS generates RF signals using a reference clock supplied from an external source and data programmed into the DDS's registers. DDS uses the reference clock to generate an internal system clock as a multiple of the reference clock. DDS uses the system clock to read the data programmed into the registers to generate a digital signal output. DDS also generates a synchronization clock to be used by external hardware to synchronize the external hardware with the DDS's internal system clock. Carrier frequency DDS ( 301 ) and modulation frequency DDS( 302 ) is a control register ( to set the output frequency and phase offset 303 It may include a core architecture consisting of a phase accumulator using data programmed into ), and at the output, a phase-versus-amplitude sine or cosine lookup table removes high-frequency sampling images to output a pure sine wave digital signal. In a specific embodiment, the carrier frequency DDS ( 301 ) can be an M-bit DDS (e.g., a 32-bit sinus DDS) and a modulation frequency DDS ( 302 ) may be an N-bit DDS (e.g., a 32-bit sinus DDS). Digital signal forms successfully used include square wave forms, sine wave forms, rectified sine wave forms, triangle or other waveforms and / or combinations thereof.

[0063] Control register ( 303 ) is a controller( 201Data and / or commands for setting the output frequency and phase offset of the output digital signal can be received from ).

[0064] Carrier Frequency DDS ( 301 ) can generate an M-bit carrier frequency digital signal, and modulation frequency DDS( 302 ) can generate an N-bit modulated frequency digital signal. The N-bit modulated frequency digital signal is the ALU( 305 It can be modulated to control the modulation degree of the modulation frequency digital signal before being input to ). In one embodiment, ALU ( 305 ) can numerically calculate a modulated digital output signal in real time from a carrier frequency digital signal and a modulation frequency digital signal. For example, a digital frequency synthesizer ( 204 ) can output a K-bit (e.g., 12-bit) parallel-modulated digital output signal. ALU( 305 It should be noted that ) can be configured to numerically calculate a digital output signal to provide amplitude modulation, frequency modulation, and / or phase modulation.

[0065] The modulated digital output signal may optionally undergo additional amplitude modulation in a digital multiplier (not shown here) before being converted to an analog RF output.

[0066] Digital frequency synthesizer ( 204 ) is also a clock oscillator ( 203 Carrier frequency DDS using the reference clock generated by ) 301 ) and modulation frequency DDS( 302 Includes a PLL frequency multiplier configured to generate an internal system clock for ). Clock oscillator ( 203) may be a precision temperature-compensated crystal oscillator with an initial accuracy of + / - 1 ppm. In an exemplary embodiment, the internal system clock may be set to 128 MHz and the reference clock may be set to 16 MHz.

[0067] Figure 3 shows a single modulation frequency DDS ( 302 () is an example, but the present disclosure is not limited thereto, and it should be noted that a digital frequency synthesizer may include one or more modulation frequency generators capable of simultaneously transmitting multiple modulation frequency digital signals.

[0068] Looking again at Fig. 2, a digital frequency synthesizer ( 204 The modulated digital output signal from ) is converted into an analog RF signal by a DAC converter ( 205 It can be input to the DAC converter ( 205 The RF signal from ) is amplifier( 206 )(e.g., a linear RF power amplifier in a bridge configuration), optional converter (e.g., a balun) (not shown here), filter circuit ( 207 It passes through a )(e.g., a 5th-order elliptical Kaur filter), and then the probe( 102 It is output as ). Filter circuit ( 207 ) is a coaxial cable ( 104 ) and impedance converter( 209 probe( 102 It can be connected to ) [the impedance of the object is the emitting device ( 101 [Configured to substantially match the output impedance of )]. Probe( 102 When ) is applied to the patient's oral cavity, the probe / patient combination is 150+j 200 It was determined through impedance measurement, exhibiting a complex impedance of approximately Ohms. Impedance converter ( 209 ) defines this complex impedance as the impedance of the coaxial cable, and accordingly, the filter circuit ( 207It acts to match the output impedance of ). This promotes power transmission and minimizes reflection. In an additional example, a conductive isolated probe ( 102 ) was used at a frequency of approximately 433 MHz coupled to the outer ear channel. Due to different probe designs and coupling methods in this frequency band, the values ​​of the matching elements may differ or even be omitted. Then, the probe ( 102 ) can be considered as an antenna matched to a capacitive coupler or a capacitive load.

[0069] In a specific embodiment, a filter circuit ( 207 The output from ) is a directional coupler ( 208 It can pass through ). Directional coupler ( 208 The output signal from ) is the controller( 201 It can be supplied to the two ADC inputs of ), where the amplitude and ratio of the two signals are the controller ( 201 ) to make the probe( 102 It enables continuous monitoring of both the signal output power / frequency and the quality of probe contact with the target. This information allows the controller ( 201 It can be used by ). Then, the controller ( 201 ) takes appropriate measures, for example, display( 212 Display an error message on ) and the emission device ( 101 Providing appropriate calibration signals to one or more parts of ), determining and controlling the amount of power applied to the subject, evaluating patient treatment compliance, and memory ( 202 Record indicators of patient treatment adherence in ).

[0070] Directional coupler ( 208 ) is a filter circuit ( 207It can operate to couple a portion of the energy emitted by the directional coupler to the detection circuit through the output connector. The output connector is connected to the primary input of the directional coupler, and the coaxial cable is connected to the primary output of the directional coupler. The directional coupler includes two secondary outputs, each connected to a detection circuit. The primary detection circuit functions to detect the amount of power applied to the patient, and the secondary detection circuit functions to detect the amount of power reflected from the patient. The primary detection circuit is connected to the positive input of the differential amplifier through a resistor divider. The secondary detection circuit is connected to the negative input of the differential amplifier through a resistor divider. The output of the differential amplifier represents the difference between the power delivered to the patient and the power reflected from the patient by the filter circuit, and thus represents the amount of power absorbed by the patient. The output of the differential amplifier is applied to an analog-to-digital converter (ADC) or a comparator, and its output is to the controller ( 201 It connects to ).

[0071] Digital frequency synthesizer combined with a linear output stage ( 204 The complete digital synthesis of the modulated digital signal in ) allows for the modulation of authorized radiation using other modulation types in addition to amplitude modulation.

[0072] emission device ( 101 ) is also a emitting device ( 101 A power source for supplying power to one or more parts of ) 210 It may include ). Power ( 210 ) can be an energy storage system such as a battery, supercapacitor, lithium-ion battery, fuel cell, or other energy storage device. Power source( 210 ) can be recharged directly from a power source, such as an AC power outlet or a docking station, or using inductive charging. In a specific embodiment, the controller ( 201 ) is power ( 210It can monitor the power level of ) and provide a warning to the user when the power level reaches a threshold level. In addition, the controller ( 201 ) is a emitting device ( based on power level) 101 ) or emission device( 101 It can perform operations such as switching off one or more parts of ) (and / or initiating low-power mode).

[0073] Optionally, the docking station powers ( 210 It may be included in a system (not shown herein) configured to recharge ). The docking station includes a communication interface, a user authentication module, an activation module [emission device ( 101 It may include parts such as [for activating )] or any other currently or subsequently known parts.

[0074] emission device ( 101 ) is also a controller ( 201 ) is an emitting device such as a server, electronic device, docking station, etc. ( 101 A communication interface that enables communication with external devices ( 211 It may include ). Examples of communication interfaces may include, but are not limited to, serial interfaces, e.g., RS-232, USB (Universal Serial Bus), SCSI (Small Computer Systems Interface), Ethernet, RS-422, or wireless communication interfaces, e.g., Wi-Fi, Bluetooth, Near Field Communication (NFC), or other wireless interfaces. Controller ( 201 ) is a communication interface ( in any communication protocol such as ADI (Automation / Drive Interface) 211 It can communicate with external devices through ).

[0075] As discussed above, the emission device ( 101 ) is also a display( 212 )[Emission device(101 Can display various indicators / warnings regarding the operation of )], user interface( 213 )(e.g., keyboard, microphone, touch interface, etc. configured for user commands) and other output component(s)( 214 It may include )(e.g., LED, speaker, etc.).

[0076] In a specific embodiment, the emitting device ( 101 ) is the emitting device ( during a specific treatment session 101 It may include an activation module (not shown herein) for activating ). Treatment sessions may be user-specific and may be determined based on authentication information received from the user. For example, treatment sessions may be activated for the user based on the user's disease state. Various parameters of a treatment session may include, but are not limited to, the total duration of emission for the treatment session, the power level of the emission, the duty cycle of the emission (i.e., the ratio of the uptime to the downtime of the pulsed emission applied during treatment), the order of application of different modulation frequencies for special application, and the total number of treatments prescribed for a specific subject and the duration of each treatment, and combinations thereof.

[0077] The activation module is, for example, a user interface (e.g., fingerprint, retinal scan, login credentials, etc.), an emission device ( 101 An activation card (e.g., RFID chip card, ISO chip card, contactless (NFC) card, etc.) and / or an emitting device such as a docking station that communicates with the activation interface of ) 101 Authentication information can be received from the user through an external device that communicates with ).

[0078] emission device ( 101 ) controller( 201) analyzes information provided by a directional coupler to determine and control the amount of power applied to the patient, evaluate patient treatment adherence, and possibly store indicators of patient treatment adherence in memory for subsequent analysis and evaluation by a physician or other clinician. 202 It can be operated to record in ).

[0079] Examples of treatments performed on patients included types of tumors of the brain, bladder, colorectal, kidney, mesothelial, neuroendocrine, liver, biliary, lung, breast, ovary, pancreas, prostate, and thyroid. The treatment involved applying an amplitude-modulated carrier signal at a specific frequency in the range of about 0.1 to about 150,000 Hz with very high precision and stability. The carrier signal may be about 1 KHz to 5000 MHz, or about 0.1 to 1000 MHz, or about 1 to 500 MHz, or about 1 to 100 MHz, or about 5 to 50 MHz, or about 10 MHz to about 40 MHz, or about 15 MHz to about 30 MHz, or any other frequency (e.g., 27 MHz) where the subject's body can be utilized as an antenna. One or more modulation frequencies may be emitted simultaneously or sequenced to form the modulation signal. The modulation frequency digital signal may be within about 0.1 Hz to about 150,000 Hz, more preferably about 100 Hz to about 99,000 Hz. One or more modulation frequencies may be determined and selected based on the type of cancer or disease state to be treated. Additional examples of treatment modes for specific types of tumors (at specific AM frequencies that are precisely controlled) are described in detail below.

[0080] Fig. 6 shows a discharge device ( 101 Illuminates an example of internal hardware that may be included in any electronic component of ). electric bus ( 600 ) serves as an information highway that interconnects other exemplified parts of the hardware. Processor(605 A ) is a central processing unit of a system configured to perform computational and logical operations necessary to execute programming instructions. As used in this document and the claims, the terms “processor” and “processing unit” may refer to any number of processors or a single processor in a set of processors that collectively perform a set of tasks, such as a central processing unit (CPU), a graphics processing unit (GPU), a remote server, or a combination thereof. Read-only memory (ROM), random access memory (RAM), flash memory, hard drives, and other devices capable of storing electronic data are memory devices ( 625 It constitutes an example of ). A memory device may include a set of devices or a single device in which data and / or instructions are stored.

[0081] Optional display interface ( 630 ) is a bus( 600 Information from ) in visual, graphic, or alphanumeric format on a display device ( 635 It may be allowed to be displayed on ). An audio interface and audio output (e.g., speakers) may also be provided. Communication with external devices is made possible by various communication devices such as wireless antennas, RFID tags, and / or short-range or near-range communication transceivers ( 640 It can occur using ), and each of these can be optionally communicated with other parts of the device through one or more communication systems. Communication device ( 640 ) can be configured to be connected to a communication network such as the Internet, a local area network, or a cellular phone data network.

[0082] Hardware includes input devices such as keyboards, mice, joysticks, touchscreens, touchpads, remote controls, pointing devices, and / or microphones (650 A user interface sensor that allows the reception of data from ) 645 It may additionally include ). A digital image frame can also include a camera ( capable of capturing video and / or still images) 620 It can be received from ). The hardware can also include one or more sensors such as a position sensor (Global Positioning System), temperature sensor, pulse sensor, heart pressure monitor, resistance sensor, etc. 660 It may include ).

[0083] Frequency effective for treating a specific disease state or cancer may be discovered using any method currently or subsequently known. Frequency discovery may involve exposing one or more subjects pre-diagnosed with a specific health condition (e.g., a specific type of cancer) to a precision modulation frequency applied to these subjects or subjects, and measuring variations in one or more physiological responses of the patient(s). The frequency determined in this manner may be used to determine disease-specific modulation frequencies by further screening healthy subjects. Control measurements may be obtained by exposing one or more subjects not suffering from the specific health condition (e.g., a specific type of cancer) to the modulation frequency applied to these subjects or subjects, and measuring variations in one or more physiological responses of said patient(s). For example, frequency discovery may involve measuring variations in the subject's skin electrical resistance, pulse amplitude, and / or blood pressure while exposed to a modulation frequency generated using the methods and systems disclosed herein. For frequency discovery, the subject may be gradually exposed to a modulation frequency of about 0.1 Hz to about 150,000 Hz (e.g., using increments of about 50 Hz to about 150 Hz, preferably about 75 Hz to about 125 Hz), and variations in skin electrical resistance, pulse amplitude, and / or blood pressure may be measured. Whenever a change is observed in the measured skin electrical resistance (change in threshold), pulse amplitude (over about 1 to 2 beats), and / or blood pressure (change in threshold), the exposure to the corresponding modulation frequency may be increased in increasingly smaller increments (e.g., 10 -4 to 10 -3It can be repeated using Hz. The frequency that elicits the best biofeedback response is selected as the tumor-specific frequency. For example, if fluctuations in pulse amplitude are used, the best biofeedback response may be defined by the magnitude of the increased amplitude and / or the number of beats with increased amplitude. Such frequency detection can be performed on subjects at different disease stages, such as disease progression, stable disease, and / or partial response. The selection of the specific frequency can be performed according to the method described in the literature [Barbault et al. 2009 J. Exp. Clin. Cancer Res. 28(1): 51].

[0084] By using the above method, the method and system of the present disclosure provide, without limitation, a safe and promising novel therapeutic mode for a number of cancer types such as breast cancer, pancreatic cancer, non-small cell and small cell lung cancer, neuroendocrine tumors, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, multiple myeloma, leukemia, and colorectal cancer.

[0085] Amplitude modulation frequencies found to be effective in treating different types of cancer are listed below. Generally, in the treatment of subjects suffering from the presented forms of cancer, it may be desirable to apply all frequencies determined to be specific to the particular type of cancer. However, a limited number of determined frequencies, for example, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed frequencies, may produce a beneficial effect.

[0086]

[0087]

[0088]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095]

[0096] In certain embodiments, the arm-specific AM frequencies provided in Table A may also be used in combination with one or more of the AM frequencies disclosed in the '365 patent. One or more of the AM frequencies in Table A may be combined with one or more of the frequencies provided in Tables 2, 4, 7, 13, 16, 18, 20, and 23 through 32 below. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a cancer treatment method, wherein the frequencies are selected from Table A, and optionally from Tables 2, 4, 7, 13, 16, 18, 20, and 23 to 32, provided that at least one frequency is selected from Table A.

[0097] The apparatus and method described herein for treating different types of cancer by applying an electromagnetic field amplitude-modulated at a specific and cancer-specific frequency to a patient may be used as a standalone cancer therapy or in combination with other currently or subsequently known modes of cancer treatment. The apparatus and method described herein may be used in combination with surgical intervention, radiation therapy, and / or chemotherapy.

[0098] When used in combination with other cancer therapies, the treatment method described in this disclosure may be used as an adjuvant or neoadjuvant therapy in cancer treatment. In the case of neoadjuvant therapy, the treatment method described in this disclosure is administered to the subject prior to primary treatment. Such neoadjuvant therapy may be authorized to reduce the extent and / or size of the cancer before using a more radical therapeutic intervention, or to lower the risk of recurrence and / or metastasis after primary treatment. The use of the disclosed method as neoadjuvant therapy may reduce side effects and / or improve the outcomes of more extensive treatments by making primary treatment easier and more likely to succeed. Primary treatment may be surgical intervention, radiation therapy, and / or chemotherapy.

[0099] The treatment method described in the present disclosure may be used as an adjuvant therapy, which is administered in addition to the primary therapy to enhance its effect. The primary therapy may be surgery, radiation therapy, and / or chemotherapy. The adjuvant therapy may be administered concurrently with and / or after the primary therapy. The adjuvant therapy may be used to reduce or prevent the recurrence of cancer after the subject has been treated by a primary therapy, such as surgery, radiation therapy, and / or chemotherapy.

[0100] Treatment of breast cancer

[0101] Breast cancer may be treated according to the method disclosed herein by the application of breast cancer-specific amplitude-modulated frequencies. Breast cancer-specific frequencies are provided in Table 1 below. Patients with breast cancer may be treated with any number of the frequencies provided in Table 1, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed breast cancer-specific frequencies may be used for breast cancer treatment. It should be noted that while the table below provides specific frequencies for breast cancer treatment, the present disclosure is not so limiting, and other frequencies found to be effective for breast cancer treatment are also within the scope of the present disclosure. Additionally, each frequency listed below includes a value that is not exactly that number or range, but close to it (i.e., within + / - 0.1 Hz).

[0102]

[0103]

[0104] In certain embodiments, the frequencies listed above may also be used in combination with one or more frequencies disclosed in the '365 patent. Specifically, a treatment mode for the treatment of breast cancer according to the present disclosure may include the application of one, some or all of the frequencies listed above in combination with one or more frequencies disclosed in Table 2 for breast cancer. Alternatively and / or additionally, frequencies disclosed in the '365 patent may be used for the treatment of breast cancer using the method and system described herein.

[0105]

[0106]

[0107] One or more of the AM frequencies in Table 1 may be used in combination with one or more of the frequencies provided in Table 2. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a breast cancer treatment method, wherein the frequencies are selected from Table 1 and optionally from Table 2, provided that at least one frequency is selected from Table 1.

[0108] Treatment of neuroendocrine tumors

[0109] Neuroendocrine tumors may be treated according to the method disclosed herein by the application of neuroendocrine tumor-specific amplitude-modulated frequencies. Neuroendocrine tumor-specific frequencies are provided in Table 3 below. Patients suffering from neuroendocrine tumors may be treated with any number of the frequencies provided in Table 3, but generally, it is desirable to use as many frequencies as are practical for the treatment of the patient. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed neuroendocrine tumor-specific frequencies may be used for the treatment of neuroendocrine tumors. It should be noted that while the following table provides specific frequencies for the treatment of neuroendocrine tumors, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of neuroendocrine tumors are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0110]

[0111] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the '365 patent. Specifically, a treatment mode for the treatment of a neuroendocrine tumor according to the present disclosure may include the application of all or part of the frequencies listed above in combination with one or more of the frequencies disclosed in Table 4 for neuroendocrine cancer. Alternatively and / or additionally, the frequencies disclosed in the '365 patent may be used for the treatment of a neuroendocrine tumor using the methods and systems described herein.

[0112]

[0113] One or more of the AM frequencies in Table 3 may be combined with one or more of the frequencies provided in Table 4. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a breast cancer treatment method, wherein the frequencies are selected from Table 3 and optionally from Table 4, provided that at least one frequency is selected from Table 3.

[0114] Treatment of non-Hodgkin lymphoma

[0115] Non-Hodgkin lymphoma may be treated according to the method disclosed herein by the application of non-Hodgkin lymphoma-specific amplitude-modulated frequencies. Non-Hodgkin lymphoma tumor-specific frequencies are provided in Table 5 below. Patients with non-Hodgkin lymphoma may be treated with any number of frequencies provided in Table 5, but generally, it is desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more of the listed non-Hodgkin lymphoma-specific frequencies may be used for the treatment of non-Hodgkin lymphoma tumors. It should be noted that while the following table provides specific frequencies for the treatment of non-Hodgkin lymphoma tumors, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of non-Hodgkin lymphoma tumors are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0116]

[0117] Treatment of pancreatic adenocarcinoma

[0118] Pancreatic adenocarcinoma can be treated according to the method disclosed herein by applying a pancreatic adenocarcinoma-specific amplitude modulation frequency. Pancreatic adenocarcinoma-specific frequencies are provided in Table 6 below. Patients with pancreatic adenocarcinoma may be treated by any number of the frequencies provided in Table 6, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed specific frequencies may be used for the treatment of pancreatic adenocarcinoma. It should be noted that while the following table provides specific frequencies for the treatment of pancreatic adenocarcinoma, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of pancreatic adenocarcinoma are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0119]

[0120]

[0121] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the '365 patent. Specifically, a treatment mode for the treatment of pancreatic adenocarcinoma according to the present disclosure may include the application of all or part of the frequencies listed above in combination with one or more of the frequencies disclosed in Table 7. Alternatively and / or additionally, the frequencies disclosed in the '365 patent may be used to treat a pancreatic adenocarcinoma condition using the method and system described herein.

[0122]

[0123] One or more of the AM frequencies in Table 6 may be used in combination with one or more of the frequencies provided in Table 7. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a method for treating pancreatic adenocarcinoma, wherein the frequencies are selected from Table 6 and optionally from Table 7, provided that at least one frequency is selected from Table 6.

[0124] Treatment of head and neck cancer

[0125] Head and neck cancer may be treated according to the method disclosed herein by the application of head and neck cancer-specific amplitude-modulated frequencies. Head and neck cancer-specific frequencies are provided in Table 8 below. Patients with head and neck cancer may be treated with any number of frequencies provided in Table 8, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, at least 10 or 15 of the listed head and neck cancer-specific frequencies may be used for the treatment of head and neck cancer. While the following table provides specific frequencies for the treatment of head and neck cancer, it should be noted that the present disclosure is not so limiting, and other frequencies found to be effective for the treatment of head and neck cancer are also within the scope of the present disclosure. Furthermore, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0126]

[0127] Treatment of stomach cancer

[0128] Gastric cancer may be treated according to the method disclosed herein by the application of gastric cancer-specific amplitude-modulated frequencies. Gastric cancer-specific frequencies are provided in Table 9 below. Patients with gastric cancer may be treated by any number of frequencies provided in Table 9, but generally, it is desirable to use as many frequencies as are practical for the treatment of gastric cancer. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed gastric cancer-specific frequencies may be used for the treatment of gastric cancer. It should be noted that while the following table provides specific frequencies for the treatment of gastric cancer, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of gastric cancer are within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0129]

[0130] Treatment of glioblastoma

[0131] Glioblastoma may be treated according to the method disclosed herein by the application of glioblastoma-specific amplitude-modulated frequencies. Glioblastoma-specific frequencies are provided in Table 10 below. Patients with glioblastoma may be treated by any number of frequencies provided in Table 10, but generally, it is desirable to use as many frequencies as are practical for the treatment of the patient. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed glioblastoma-specific frequencies may be used for the treatment of glioblastoma. It should be noted that while the following table provides specific frequencies for the treatment of glioblastoma, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of glioblastoma are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0132]

[0133] Treatment of squamous cell carcinoma of the anal canal

[0134] Squamous cell carcinoma of the anal canal can be treated according to the method disclosed herein by applying anal canal-specific amplitude modulation frequencies to the squamous cell carcinoma. Squamous cell carcinoma of the anal canal-specific frequencies are provided in Table 11 below. Patients suffering from squamous cell carcinoma of the anal canal may be treated by any number of frequencies provided in Table 11, but generally, it is desirable to use as many frequencies as are practical for the treatment of the patient. Accordingly, among the listed squamous cell carcinoma of the anal canal-specific frequencies, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more may be used for the treatment of squamous cell carcinoma of the anal canal. The table below provides specific frequencies for the treatment of squamous cell carcinoma of the anal canal, but the present disclosure is not so limited, and other frequencies found to be effective for the treatment of squamous cell carcinoma of the anal canal are also within the scope of the present disclosure. Additionally, each frequency listed below includes a value that is not exactly that number or range but is close to it (i.e., within + / - 0.1 Hz).

[0135]

[0136] Treatment of hepatocellular carcinoma

[0137] Hepatocellular carcinoma may be treated according to the method disclosed herein by the application of hepatocellular carcinoma-specific amplitude modulation frequencies. Hepatocellular carcinoma-specific frequencies are provided in Table 12 below. Patients with hepatocellular carcinoma may be treated by any number of frequencies provided in Table 12, but it is generally desirable to use as many frequencies as are practical for the treatment of the patient. Accordingly, at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 of the listed hepatocellular carcinoma-specific frequencies may be used for the treatment of hepatocellular carcinoma. It should be noted that while the following table provides specific frequencies for the treatment of hepatocellular carcinoma, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of hepatocellular carcinoma are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0138]

[0139]

[0140] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the '365 patent. Specifically, a treatment mode for the treatment of hepatocellular carcinoma according to the present disclosure may include the application of all or part of the frequencies listed above in combination with one or more of the frequencies disclosed in Table 13 for hepatocellular carcinoma. Alternatively and / or additionally, the frequencies disclosed in the '365 patent may be used for the treatment of a hepatocellular carcinoma condition using the method and system described herein.

[0141]

[0142]

[0143] One or more of the AM frequencies in Table 12 may be used in combination with one or more of the frequencies provided in Table 13. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a method for treating hepatocellular carcinoma, wherein the frequencies are selected from Table 12 and optionally from Table 13, provided that at least one frequency is selected from Table 12.

[0144] Treatment of cholangiocarcinoma

[0145] Cholangiocarcinoma may be treated according to the method disclosed herein by the application of cholangiocarcinoma-specific amplitude modulation frequencies. Cholangiocarcinoma-specific frequencies are provided in Table 14 below. Patients with cholangiocarcinoma may be treated by any number of frequencies provided in Table 14, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed cholangiocarcinoma-specific frequencies may be used for the treatment of cholangiocarcinoma. It should be noted that while the following table provides specific frequencies for the treatment of cholangiocarcinoma, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of cholangiocarcinoma are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0146]

[0147]

[0148] Treatment of mesothelioma

[0149] Mesothelioma may be treated according to the method disclosed herein by the application of mesothelioma-specific amplitude modulation frequencies. Mesothelioma-specific frequencies are provided in Table 15 below. Patients with mesothelioma may be treated by any number of frequencies provided in Table 15, but generally, it is desirable to use as many frequencies as are practical for the treatment of the patient. Accordingly, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed mesothelioma-specific frequencies may be used for the treatment of mesothelioma. It should be noted that while the following table provides specific frequencies for the treatment of mesothelioma, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of mesothelioma are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0150]

[0151] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the '365 patent. Specifically, a treatment mode for the treatment of mesothelioma according to the present disclosure may include the application of all or part of the frequencies listed above in combination with one or more of the frequencies disclosed in Table 16 for mesothelioma. Alternatively and / or additionally, the frequencies disclosed in the '365 patent may be used for the treatment of mesothelioma using the method and system described herein.

[0152]

[0153] One or more of the AM frequencies in Table 15 may be used in combination with one or more of the frequencies provided in Table 16. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a method for treating mesothelioma, wherein the frequencies are selected from Table 15 and optionally from Table 16, provided that at least one frequency is selected from Table 15.

[0154] Treatment of thyroid cancer

[0155] Thyroid cancer may be treated according to the method disclosed herein by the application of thyroid cancer-specific amplitude-modulated frequencies. Thyroid cancer-specific frequencies are provided in Table 17 below. Patients with thyroid cancer may be treated by any number of frequencies provided in Table 17, but generally, it is desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed thyroid cancer-specific frequencies may be used for the treatment of thyroid cancer. It should be noted that while the following table provides specific frequencies for the treatment of thyroid cancer, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of thyroid cancer are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0156]

[0157] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the '365 patent. Specifically, a treatment mode for the treatment of thyroid cancer according to the present disclosure may include the application of all or part of the frequencies listed above in combination with one or more of the frequencies disclosed in Table 18 for thyroid cancer. Alternatively and / or additionally, the frequencies disclosed in the '365 patent may be used for the treatment of thyroid cancer using the method and system described herein.

[0158]

[0159]

[0160] One or more of the AM frequencies in Table 17 may be used in combination with one or more of the frequencies provided in Table 18. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a method for treating thyroid cancer, wherein the frequencies are selected from Table 17 and optionally from Table 18, provided that at least one frequency is selected from Table 17.

[0161] Treatment of prostate cancer

[0162] Prostate cancer may be treated according to the method disclosed herein by the application of prostate cancer-specific amplitude-modulated frequencies. Prostate cancer-specific frequencies are provided in Table 19 below. Patients with prostate cancer may be treated by any number of frequencies provided in Table 19, but generally, it is desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed prostate cancer-specific frequencies may be used for the treatment of prostate cancer. It should be noted that while the following table provides specific frequencies for the treatment of prostate cancer, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of prostate cancer are also within the scope of the present disclosure. In addition, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0163]

[0164] In certain embodiments, the frequencies listed above may also be used in combination with one or more frequencies disclosed in the '365 patent. Specifically, a treatment mode for the treatment of prostate cancer according to the present disclosure may include the application of all or part of the frequencies listed above in combination with one or more of the frequencies disclosed in Table 20 for prostate cancer. Alternatively and / or additionally, frequencies disclosed in the '365 patent may be used for the treatment of prostate cancer using the method and system described herein.

[0165]

[0166] One or more of the AM frequencies in Table 19 may be used in combination with one or more of the frequencies provided in Table 20. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a method for treating prostate cancer, wherein the frequencies are selected from Table 19 and optionally from Table 20, provided that at least one frequency is selected from Table 19.

[0167] Treatment of rhabdomyosarcoma

[0168] Rhabdomyosarcoma can be treated according to the method disclosed herein by the application of rhabdomyosarcoma-specific amplitude modulation frequencies. Rhabdomyosarcoma-specific frequencies are provided in Table 21 below. Patients suffering from rhabdomyosarcoma may be treated by any number of frequencies provided in Table 21, but generally, it is desirable to use as many frequencies as are practical for the treatment of the patient. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed rhabdomyosarcoma-specific frequencies may be used for the treatment of rhabdomyosarcoma. The table below provides specific frequencies for the treatment of rhabdomyosarcoma, but it should be noted that the present disclosure is not so limited and other frequencies found to be effective for the treatment of rhabdomyosarcoma are also within the scope of the present disclosure. Additionally, each frequency listed below includes a value that is not exactly that number or range, but is close to it (i.e., within + / - 0.1 Hz).

[0169]

[0170] Treatment of colorectal cancer

[0171] Colorectal cancer can be treated according to the method disclosed herein by the application of colorectal cancer-specific amplitude modulation frequencies. Colorectal cancer-specific frequencies are provided in Table 22 below. Patients with colorectal cancer may be treated by any number of frequencies provided in Table 22, but generally, it is desirable to use as many frequencies as are practical for the treatment of the patient. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed colorectal cancer-specific frequencies may be used for the treatment of colorectal cancer. The table below provides specific frequencies for the treatment of colorectal cancer, but it should be noted that the present disclosure is not so limited and other frequencies found to be effective for the treatment of colorectal cancer are also within the scope of the present disclosure. Additionally, each frequency listed below includes a value that is not exactly that number or range, but close to it (i.e., within + / - 0.1 Hz).

[0172]

[0173] In certain embodiments, the frequencies listed above may also be used in combination with one or more of the frequencies disclosed in the '365 patent (reproduced below). Specifically, a treatment mode for the treatment of colorectal cancer according to the present disclosure may include applying all or part of the frequencies listed above in combination with one or more of the frequencies disclosed in Table 23 for colorectal cancer. Alternatively and / or additionally, the frequencies disclosed in the '365 patent may be used for the treatment of colorectal cancer using the methods and systems described herein.

[0174]

[0175] One or more of the AM frequencies in Table 22 may be used in combination with one or more of the frequencies provided in Table 23. In a preferred embodiment, 10 or more, 15 or more, or 20 or more, 25 or more, or 30 or more, 35 or more, or 40 or more, 45 or more, or 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more frequencies are used in a method for treating colorectal cancer, wherein the frequencies are selected from Table 22 and optionally from Table 23, provided that at least one frequency is selected from Table 22.

[0176] In a specific embodiment, the frequency disclosed in the '365 patent may be used to treat a diseased condition using the method and system described herein.

[0177] Treatment of ovarian cancer

[0178] Ovarian cancer may be treated according to the method disclosed herein by the application of ovarian cancer-specific amplitude modulation frequencies. Ovarian cancer-specific frequencies are provided in Table 24 below. Patients with ovarian cancer may be treated by any number of frequencies provided in Table 24, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more of the listed ovarian cancer-specific frequencies may be used for the treatment of ovarian cancer. It should be noted that while the following table provides specific frequencies for the treatment of ovarian cancer, the present disclosure is not so limiting, and other frequencies found to be effective for the treatment of ovarian cancer are within the scope of the present disclosure.

[0179]

[0180]

[0181]

[0182] Treatment of kidney cancer

[0183] Kidney cancer may be treated according to the method disclosed herein by the application of kidney cancer-specific amplitude-modulated frequencies. Kidney cancer-specific frequencies are provided in Table 25 below. Patients with kidney cancer may be treated by any number of frequencies provided in Table 25, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, or 35 or more of the listed kidney cancer-specific frequencies may be used for the treatment of kidney cancer. While the following table provides specific frequencies for the treatment of kidney cancer, it should be noted that the present disclosure is not so limited, and other frequencies found to be effective for the treatment of kidney cancer are within the scope of the present disclosure.

[0184]

[0185] Treatment of bladder cancer

[0186] Bladder cancer may be treated according to the method disclosed herein by the application of bladder cancer-specific amplitude-modulated frequencies. Bladder cancer-specific frequencies are provided in Table 26 below. Patients with bladder cancer may be treated by any number of frequencies provided in Table 26, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, or 30 or more of the listed bladder cancer-specific frequencies may be used for the treatment of bladder cancer. While the following table provides specific frequencies for the treatment of bladder cancer, it should be noted that the present disclosure is not so limited and other frequencies found to be effective for the treatment of bladder cancer are also within the scope of the present disclosure.

[0187]

[0188] Treatment of lung cancer

[0189] Lung cancer may be treated according to the method disclosed herein by the application of lung cancer-specific amplitude-modulated frequencies. Lung cancer-specific frequencies are provided in Table 27 below. Patients with lung cancer may be treated by any number of frequencies provided in Table 27, but generally, it is desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more of the listed lung cancer-specific frequencies may be used for lung cancer treatment. It should be noted that while the following table provides specific frequencies for lung cancer treatment, the present disclosure is not so limiting, and other frequencies found to be effective for lung cancer treatment are within the scope of the present disclosure.

[0190]

[0191] Treatment of leiomyosarcoma

[0192] Leiomyosarcoma may be treated according to the method disclosed herein by the application of leiomyosarcoma-specific amplitude modulation frequencies. Leiomyosarcoma-specific frequencies are provided in Table 28 below. Patients suffering from leiomyosarcoma may be treated by any number of frequencies provided in Table 28, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, or 35 or more of the listed leiomyosarcoma-specific frequencies may be used for the treatment of leiomyosarcoma. While the following table provides specific frequencies for the treatment of leiomyosarcoma, it should be noted that the present disclosure is not so limited, and other frequencies found to be effective for the treatment of leiomyosarcoma are within the scope of the present disclosure.

[0193]

[0194] Treatment of leukemia and chronic lymphoid cancer

[0195] Leukemia and chronic lymphoid cancer may be treated according to the method disclosed herein by the application of amplitude-modulated frequencies specific to leukemia and chronic lymphoid cancer. Leukemia and chronic lymphoid cancer-specific frequencies are provided in Table 29 below. Patients suffering from leukemia and chronic lymphoid cancer may be treated by any number of frequencies provided in Table 29, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, at least 10, or at least 15 of the listed leukemia and chronic lymphoid cancer-specific frequencies may be used for the treatment of leukemia and chronic lymphoid cancer. While the following table provides specific frequencies for the treatment of leukemia and chronic lymphoid cancer, it should be noted that the present disclosure is not so limited, and other frequencies found to be effective for the treatment of leukemia and chronic lymphoid cancer are within the scope of the present disclosure.

[0196]

[0197] Treatment of multiple myeloma

[0198] Myeloma may be treated according to the method disclosed herein by the application of myeloma-specific amplitude-modulated frequencies. Myeloma-specific frequencies are provided in Table 30 below. Patients with myeloma may be treated by any number of frequencies provided in Table 30, but generally, it is desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, 10 or more, 15 or more, or 20 or more of the listed myeloma-specific frequencies may be used for the treatment of myeloma. It should be noted that while the following table provides specific frequencies for the treatment of myeloma, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of myeloma are also within the scope of the present disclosure.

[0199]

[0200] Treatment of lymphoma

[0201] Lymphoma may be treated according to the method disclosed herein by the application of lymphoma-specific amplitude-modulated frequencies. Lymphoma-specific frequencies are provided in Table 31 below. Patients suffering from lymphoma may be treated by any number of frequencies provided in Table 31, but generally, it is desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, at least 10, or at least 15 of the listed lymphoma-specific frequencies may be used for the treatment of lymphoma. While the following table provides specific frequencies for the treatment of lymphoma, it should be noted that the present disclosure is not so limited and other frequencies found to be effective for the treatment of lymphoma are also within the scope of the present disclosure.

[0202]

[0203] Treatment of brain cancer

[0204] Brain cancer may be treated according to the method disclosed herein by the application of brain cancer-specific amplitude-modulated frequencies. Brain cancer-specific frequencies are provided in Table 32 below. Patients with brain cancer may be treated by any number of frequencies provided in Table 32, but it is generally desirable to use as many frequencies as are practical for the patient's treatment. Accordingly, at least 10, 15, or 20, 25, or 30, 35, or 40, 45, or 50 of the listed brain cancer-specific frequencies may be used for the treatment of brain cancer. It should be noted that while the following table provides specific frequencies for the treatment of brain cancer, the present disclosure is not so limited, and other frequencies found to be effective for the treatment of brain cancer are also within the scope of the present disclosure.

[0205]

[0206] The following is an overview of exemplary uses of the electronic device of the present invention and cancer-specific frequencies for the treatment of patients:

[0207] Example A

[0208] A 79-year-old male was diagnosed with hepatitis A and hepatitis B-negative hepatocellular carcinoma. He underwent left hepatectomy the following month, which revealed the presence of poorly differentiated hepatocellular carcinoma. The largest diameter of the tumor was 10 cm, and it was staged as pT3NxMx. Five months after diagnosis, the patient showed evidence of disease progression due to four new lesions identified within the right lobe of the liver and new mediastinal adenopathy, and chemoembolization with doxorubicin and lipiodol was performed the following month. A follow-up MRI performed the following month showed disease progression. Sorafenib treatment was initiated when the patient was ECOG 1 with a KPS of 80% and Child-Pugh A6. 206 Compassionate treatment using a TheraBionic device emitting hepatocellular carcinoma (HCC)-specific frequencies was administered for 3 hours daily. The patient showed a complete response as a marker of alpha-fetoprotein (AFP) levels, decreasing from 92,620·0 international units / ml (IU / ml) before the start of treatment to 4.18 IU / ml measured one year after initial diagnosis and four months after the start of treatment with HCC-specific frequencies.

[0209] Nexavar was discontinued early in the third year following the initial diagnosis due to tolerable side effects. One month after discontinuing Nexavar, AFP levels doubled, and liver enzymes ASAP, ALAT, and Gamma GT nearly doubled, presenting evidence of early disease progression. The patient was re-examined for tumor-specific frequencies using the aforementioned method. Analysis revealed pulse pressure changes for additional HCC-specific frequencies. Fifty HCC frequencies were added to the 206 HCC frequencies, meaning the patient began receiving 256 frequencies per treatment. A new abdominal MRI obtained seven months later showed the appearance of a new tumor nodule. The patient was re-examined the following month using the aforementioned method. Analysis revealed pulse pressure changes for 12 additional HCC-specific frequencies, bringing the total to 268 HCC-specific frequencies. The same approach was applied whenever there was apparent progression indicated by changes in AFP levels and / or significant enlargement of existing tumor masses and / or the appearance of new tumor masses. The addition of a new HCC-specific frequency resulted in a reduction in AFP levels as well as a significant reduction or stabilization of the tumor mass. In the final year of treatment, the patient received a total of 422 HCC-specific frequencies.

[0210] The patient received treatment with the TheraBionic device for 67 months, during which he was unable to receive regular treatment due to a hip fracture from a fall, general weakness, and worsening renal failure. He passed away 6 months later. In summary, the addition of HCC-specific frequencies resulted in repeated objective clinical responses evaluated by radiological and tumor markers, leading to exceptionally long survival (over 6 years) in a patient with rapidly progressing advanced hepatocellular carcinoma.

[0211] Example B

[0212] An 87-year-old male with a long history of type II diabetes was diagnosed with advanced, unresectable multifocal hepatocellular carcinoma. He refused Nexavar treatment and requested self-treatment using the TheraBionic device. Two months after diagnosis, he began treatment with 313 HCC-specific frequencies. The patient maintained stable disease for 13 months with evidence of disease progression according to RECIST criteria. The following month, he began treatment with 355 HCC-specific frequencies. A follow-up abdominal MRI obtained two months later revealed the presence of necrosis within two lesions and stable disease in the remaining lesions. Therefore, the addition of 42 HCC-specific frequencies resulted in a radiological response. A follow-up abdominal MRI obtained two months later showed stable disease according to RECIST criteria. A follow-up liver MRI obtained three months later showed disease progression according to RECIST criteria, accompanied by the appearance of new liver lesions. Two weeks later, the patient was examined using the aforementioned method, and changes in pulse pressure were observed for 49 additional HCC frequencies. Accordingly, the patient began treatment with 404 frequencies in that month. Repeat abdominal MRIs obtained three months later showed stable disease. The patient continued to do well for two months following gastrointestinal bleeding caused by esophageal varices. He refused treatment for the esophageal varices and died at the end of that month. Therefore, the treatment of this patient demonstrated the clinical efficacy of additional HCC frequencies, producing both an objective response and stable disease.

[0213] background

[0214] A portable and programmable device described herein capable of transmitting an amplitude-modulated electromagnetic field at a low level has been developed. This device emits a high-precision amplitude-modulated 27 MHz high-frequency signal at a cancer-specific frequency in the range of 0.1 to 150 kHz. This device is connected to a spoon-shaped coupler that is placed in the patient's oral cavity during treatment.

[0215] Example 1: Treatment of breast cancer

[0216] Breast cancer can be treated according to the method disclosed herein by the application of a breast cancer-specific amplitude modulation frequency. Breast cancer-specific frequencies are provided in Table 33 below.

[0217]

[0218] Example 2: Treatment of neuroendocrine tumors

[0219] Neuroendocrine tumors can be treated according to the method disclosed herein by the application of a neuroendocrine tumor-specific amplitude modulation frequency. Neuroendocrine tumor-specific frequencies are provided in Table 34 below.

[0220]

[0221] Example 3: Treatment of Non-Hodgkin Lymphoma

[0222] Non-Hodgkin lymphoma tumors can be treated according to the method disclosed herein by the application of a non-Hodgkin lymphoma-specific amplitude modulation frequency. The non-Hodgkin lymphoma tumor-specific frequencies are provided in Table 35 below.

[0223]

[0224] Example 4: Treatment of pancreatic adenocarcinoma

[0225] Pancreatic adenocarcinoma can be treated according to the method disclosed herein by the application of a pancreatic adenocarcinoma-specific amplitude modulation frequency. The pancreatic adenocarcinoma-specific frequency is provided in Table 36 below.

[0226]

[0227]

[0228] Example 5: Treatment of head and neck cancer

[0229] Head and neck cancer can be treated according to the method disclosed herein by the application of head and neck cancer-specific amplitude modulation frequencies. The specific frequencies for head and neck cancer are provided in Table 37 below.

[0230]

[0231] Example 6: Treatment of gastric cancer

[0232] Gastric cancer can be treated according to the method disclosed herein by the application of a gastric cancer-specific amplitude-modulated frequency. Gastric cancer-specific frequencies are provided in Table 38 below.

[0233]

[0234] Example 7: Treatment of glioblastoma

[0235] Glioblastoma can be treated according to the method disclosed herein by the application of a glioblastoma-specific amplitude modulation frequency. Glioblastoma-specific frequencies are provided in Table 39 below.

[0236]

[0237] Example 8: Treatment of anal canal squamous cell carcinoma

[0238] Squamous cell carcinoma of the anal canal can be treated according to the method disclosed herein by the application of anal canal squamous cell carcinoma-specific amplitude modulation frequencies. Squamous cell carcinoma-specific frequencies are provided in Table 40 below.

[0239]

[0240] Example 9: Treatment of hepatocellular carcinoma

[0241] Hepatocellular carcinoma can be treated according to the method disclosed herein by the application of a hepatocellular carcinoma-specific amplitude modulation frequency. The hepatocellular carcinoma-specific frequency is provided in Table 41 below.

[0242]

[0243]

[0244] Example 10: Treatment of cholangiocarcinoma

[0245] Cholangiocarcinoma can be treated according to the method disclosed herein by the application of a cholangiocarcinoma-specific amplitude modulation frequency. The cholangiocarcinoma-specific frequencies are provided in Table 42 below.

[0246]

[0247]

[0248] Example 11: Treatment of Mesothelioma

[0249] Mesothelioma can be treated according to the method disclosed herein by the application of a mesothelioma-specific amplitude modulation frequency. Mesothelioma-specific frequencies are provided in Table 43 below.

[0250]

[0251]

[0252] Example 12: Treatment of thyroid cancer

[0253] Thyroid cancer can be treated according to the method disclosed herein by the application of a thyroid cancer-specific amplitude modulation frequency. Thyroid cancer-specific frequencies are provided in Table 44 below.

[0254]

[0255] Example 13: Treatment of prostate cancer

[0256] Prostate cancer can be treated according to the method disclosed herein by the application of a prostate cancer-specific amplitude modulation frequency. Prostate cancer-specific frequencies are provided in Table 45 below.

[0257]

[0258] Example 14: Treatment of rhabdomyosarcoma

[0259] Rhabdomyosarcoma can be treated according to the method disclosed herein by the application of a rhabdomyosarcoma-specific amplitude modulation frequency. The rhabdomyosarcoma-specific frequencies are provided in Table 46 below.

[0260]

[0261] Example 15: Treatment of colorectal cancer

[0262] Colorectal cancer can be treated according to the method disclosed herein by the application of a colorectal cancer-specific amplitude modulation frequency. Colorectal cancer-specific frequencies are provided in Table 47 below.

[0263]

[0264]

[0265] conclusion:

[0266] Treatment of cancer according to the methods and apparatus described herein is a safe and promising novel therapeutic mode for various types of cancer. After extensive testing, it was determined that the application of the frequencies provided herein to subjects enhances the efficacy of treatment and produces therapeutic effects in patients whose tumors have become resistant to the treatment. Therefore, it is desirable that most (i.e., more than 50%) or all of the determined listed frequencies be applied to subjects. The mechanism involving additional frequencies is attributed to either or both of mutual synergy between the applied frequencies or between cells affected by the additional effects of the treatment and the additional frequencies.

[0267] It is also worth noting that other patients suffering from the same type of tumor cell growth substantially exhibit the aforementioned physiological response at the same well-defined AM frequencies. Furthermore, AM frequencies that differ only slightly (less than 0.001% at high frequencies) from the listed frequencies generally induce a reduced physiological response or no physiological response at all by subjects exposed thereto at such slightly different frequencies. In this regard, the electronic system of the present invention can be modified to screen subjects for physiological responses across a wide range of frequencies to determine the presence or absence of tumor cells and, if positive, to record the defined frequency at which the physiological response was induced. These frequencies will generally match the defined frequencies listed in the above examples or any of these additional examples that may be developed, thereby allowing the characteristics of the tumor to be known. Thus, the electronic system of the present invention is a valuable diagnostic tool for diagnosing the presence or absence and identity of tumor cell growth or types of cancer. Moreover, the electronic system of the present invention is valuable for predicting whether a patient will benefit from the application of a given series of modulation frequencies. Therefore, the above system possesses the capability to predict the response to treatment, thereby improving the possibility of selecting the optimal treatment mode.

[0268] It is desirable that a well-defined sequence of frequencies be applied sequentially for a determined time period, for example, 3 seconds per frequency, but multiple frequencies may be applied simultaneously, or in any or random order. This means that an application cycle involving 180 frequencies takes nearly 10 minutes. However, beneficial effects may occur from the application of well-defined individual frequencies for different periods, for example, some for 3 seconds and some for 6 seconds.

[0269] The therapeutic dose administered to a subject suffering from tumor cell growth or the presence of cancer is determined by the duration of low-energy electromagnetic emission applied to the subject and will vary depending on the characteristics of the cancer and the subject's overall condition. However, the greatest experience has generally been gained in treating terminally ill subjects who are expected not to survive for more than about three months and have agreed to discontinue alternative forms of cancer treatment, such as chemotherapy or radiation therapy. In these severe cases, a convenient treatment schedule is recommended, for example, three one-hour treatments per day. However, when using alternative forms of application, namely forms other than an oral probe, continuous application may be possible and desirable.

[0270] Although the present invention has been described by specific embodiments, other alternatives, modifications, and variations will be apparent to those skilled in the art. Accordingly, it is intended to include all such alternatives, modifications, and variations within the spirit and scope of the appended claims.

Claims

Claim 1 A device for treating a subject suffering from cancer, comprising: a conductive applicator configured to apply radio frequency (RF) radiation, comprising amplitude-modulated output signals, to said subject; and a frequency synthesizer connected to said conductive applicator and configured to generate said amplitude-modulated output signals by generating: a carrier frequency signal having a carrier frequency of 1 KHz to 5000 MHz; A device for treating a subject suffering from cancer, wherein the amplitude modulation frequency signals having amplitude modulation frequencies of 0.1 Hz to 150,000 Hz selected to be cancer-specific frequencies; wherein the amplitude modulation frequency signals comprise at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 of the cancer-specific amplitude modulation frequencies selected from Table A below: . Claim 2 An apparatus for treating a subject suffering from cancer according to claim 1, wherein the cancer is selected from the group consisting of breast cancer, neuroendocrine tumor, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, lung cancer, kidney cancer, ovarian cancer, bladder cancer, leiomyosarcoma, multiple myeloma, lymphoma, leukemia, chronic lymphoid cancer, brain cancer, and colorectal cancer. Claim 3 An apparatus for treating a subject suffering from cancer, wherein, in claim 1, the carrier frequency is 0.1 to 1000 MHz, or 1 to 500 MHz, or 1 to 100 MHz, or 5 to 50 MHz, or 10 MHz to 40 MHz, or 15 MHz to 30 MHz. Claim 4 An apparatus for treating a subject suffering from cancer, wherein, in claim 1, the frequency synthesizer comprises: a digital carrier frequency synthesizer configured to output the carrier frequency signal; a digital modulation frequency synthesizer configured to output the amplitude modulation frequency signals; an arithmetic logic unit (ALU) configured to numerically calculate digital modulation signals in real time from the carrier frequency signal and the modulation frequency digital signal; and a digital-to-analog converter (DAC) configured to convert the digital modulation signals into the amplitude-modulation output signals. Claim 5 An apparatus for treating a subject suffering from cancer, wherein, in claim 1, the amplitude modulation frequency of each of the amplitude-modulated output signals is 100 Hz to 99,000 Hz. Claim 6 A device for treating a subject suffering from cancer, wherein, in claim 1, the amplitude modulation frequency of each of the amplitude-modulated output signals is controlled to an accuracy of 1 part per 10,000, 1 part per 100,000, or 1 part per 1,000,000 (ppm) relative to a reference amplitude modulation frequency. Claim 7 In claim 1, each of the amplitude-modulated output signals is at least 10 -5 Maintained with stability during emission, or at least 10 -6 It is maintained in stability during the release of, or at least 10 -7 A device for treating a subject suffering from cancer, wherein stability is maintained during the emission of, and said stability is determined by dividing the relative deviation of the amplitude modulation frequency by the desired amplitude modulation frequency. Claim 8 An apparatus for treating a subject suffering from cancer, wherein, in claim 1, the specific absorption rate (SAR) of the radio frequency radiation absorbed by the subject is 1 microwatt per kilogram of tissue to 50 watts per kilogram of tissue, 100 microwatts per kilogram of tissue to 10 watts per kilogram of tissue, or 0.02 milliwatts per kilogram of tissue to 400 milliwatts per kilogram of tissue. Claim 9 A device for treating a subject suffering from cancer, wherein, in claim 1, the radio frequency radiation is applied to a subject receiving treatment through an electrically conductive probe, and the electrically conductive probe is selectively configured to come into contact with the mucous membrane of the subject or the skin of the subject. Claim 10 A device for treating a subject suffering from cancer, wherein, in claim 1, the amplitude-modulated output signals are generated sequentially or simultaneously. Claim 11 A device for treating a subject suffering from cancer, wherein, in claim 1, the amplitude modulation frequency is determined or predetermined by a bio-feedback process involving the measurement of one or more physiological responses by the subject pre-diagnosed as having the cancer type when the subject is exposed to the amplitude modulation frequency. Claim 12 An apparatus for treating a subject suffering from cancer, wherein, in any one of claims 1 to 11, the radio frequency radiation comprises 40 or more of the amplitude-modulated output signals, 50 or more of the amplitude-modulated output signals, or 60 or more of the amplitude-modulated output signals, or 70 or more of the amplitude-modulated output signals, or 70 or more of the amplitude-modulated output signals, or 90 or more of the amplitude-modulated output signals, or 100 or more of the amplitude-modulated output signals. Claim 13 An apparatus for treating a subject suffering from cancer, wherein, in any one of claims 1 to 11, the cancer is breast cancer, and the subject is treated by at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100, or all of the amplitude modulation frequencies including the following: . Claim 14 In any one of claims 1 to 11, (a) the cancer is a neuroendocrine cancer, and the subject is treated by at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, at least 80, at least 90, or all of the amplitude modulation frequencies including the following: or, (b) the cancer is a non-Hodgkin lymphoma, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, or all of the amplitude modulation frequencies including the following: or, (c) the cancer is an adenocarcinoma of the pancreas, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more, or all of the amplitude modulation frequencies including the following: or, (d) the cancer is head and neck cancer, and the subject is treated by 10 or more, 15 or more, or all of the amplitude modulation frequencies including the following: or, (e) the cancer is gastric cancer, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or all of the amplitude modulation frequencies including the following: or, (f) the cancer is a glioblastoma, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more, or all of the amplitude modulation frequencies including the following: Or, (g) the cancer is a squamous cell carcinoma of the anal canal, and the subject is treated by at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, or all of the amplitude modulation frequencies including the following: or, (h) the cancer is a hepatocellular carcinoma, and the subject is treated by at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100, or all of the amplitude modulation frequencies including the following: Or, (i) the cancer is a cholangiocarcinoma, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more, or all of the amplitude modulation frequencies including the following: or, (j) the cancer is a mesothelioma, and the subject is treated by at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100, or all of the amplitude modulation frequencies including the following: or, (k) the cancer is thyroid cancer, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more, or all of the amplitude modulation frequencies including the following: Or, (l) the cancer is prostate cancer, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more, or all of the amplitude modulation frequencies including the following: Or, (m) the cancer is rhabdomyosarcoma, and the subject is treated by 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, 35 or more, 40 or more, 45 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more, or all of the amplitude modulation frequencies including the following: Or, (n) a device for treating a subject suffering from cancer, wherein the cancer is colorectal cancer, and the subject is treated by at least 10, at least 15, or at least 20, at least 25, or at least 30, at least 35, or at least 40, at least 45, or at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100, or all of the amplitude modulation frequencies including the following: . Claim 15 A device for treating a subject suffering from cancer, comprising: a conductive applicator configured to apply radio frequency radiation comprising one or more amplitude-modulated output signals to said subject; and a frequency synthesizer connected to said conductive applicator and configured to generate said one or more amplitude-modulated output signals by generating: a carrier frequency signal having a carrier frequency of 1 KHz to 5000 MHz; and an amplitude-modulated frequency signal having an amplitude-modulated frequency of 0.1 Hz to 150,000 Hz selected to be a cancer-specific frequency; wherein the frequency synthesizer comprises: a digital carrier frequency synthesizer configured to output said carrier frequency signal; a digital modulation frequency synthesizer configured to output said one or more amplitude-modulated frequency signals; and an arithmetic logic unit (ALU) configured to numerically calculate one or more digital modulation signals in real time from said carrier frequency signal and modulation frequency digital signal. A device for treating a subject suffering from cancer, comprising a digital frequency synthesizer including one or more digital modulation signals and one or more amplitude-modulation output signals configured to convert the digital frequency synthesizer (DAC) into one or more digital frequency modulation signals. Claim 16 An apparatus for treating a subject suffering from cancer according to claim 15, wherein the cancer is selected from the group consisting of breast cancer, neuroendocrine tumor, non-Hodgkin lymphoma, adenocarcinoma, head and neck cancer, gastric cancer, glioblastoma, squamous cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, mesothelioma, thyroid cancer, prostate cancer, rhabdomyosarcoma, lung cancer, kidney cancer, ovarian cancer, bladder cancer, leiomyosarcoma, multiple myeloma, lymphoma, leukemia, chronic lymphoid cancer, brain cancer, and colorectal cancer. Claim 17 An apparatus for treating a subject suffering from cancer, wherein, in paragraph 15, the carrier frequency is 0.1 to 1000 MHz, or 1 to 500 MHz, or 1 to 100 MHz, or 5 to 50 MHz, or 10 MHz to 40 MHz, or 15 MHz to 30 MHz, and / or the modulation frequency is 100 Hz to 99,000 Hz. Claim 18 An apparatus for treating a subject suffering from cancer, wherein the digital frequency synthesizer comprises: a controller configured to control the frequency and power associated with one or more amplitude-modulated output signals; and further comprises at least one of a phase-locked loop (PLL) frequency multiplier configured to set a system clock for one or more of the digital carrier frequency synthesizer and the digital modulation frequency synthesizer. Claim 19 An apparatus for treating a cancerous subject, wherein, in paragraph 18, it further comprises a directional coupler for providing power and absorption information regarding each of the one or more amplitude-modulated output signals to the controller. Claim 20 A device for treating a subject suffering from cancer, wherein, in paragraph 15, the digital carrier frequency synthesizer is a direct digital synthesizer (DDS) and / or the digital modulation frequency synthesizer is a direct digital synthesizer (DDS). Claim 21 An apparatus for treating a subject suffering from cancer, wherein, in any one of claims 15 to 20, the frequency synthesizer is configured to generate one or more amplitude-modulated output signals sequentially or simultaneously. Claim 22 A device for treating a subject suffering from cancer, wherein, in any one of claims 15 to 20, the conductive application device is configured for insertion into the oral cavity of the subject receiving treatment. Claim 23 An apparatus for treating a subject suffering from cancer, wherein, in any one of claims 15 to 20, the amplitude modulation frequency is determined or predetermined by a bio-feedback process involving the observation or measurement of a physiological response by the subject during the time in which the cellular function of the subject is excited by exposing the subject to the emission of a modulated output signal. Claim 24 delete Claim 25 delete Claim 26 delete Claim 27 delete Claim 28 delete Claim 29 delete Claim 30 delete Claim 31 delete Claim 32 delete Claim 33 delete Claim 34 delete Claim 35 delete Claim 36 delete Claim 37 delete Claim 38 delete Claim 39 delete Claim 40 delete Claim 41 delete Claim 42 delete Claim 43 delete Claim 44 delete

Images